PubRank

R H Begent

Author PubWeight™ 120.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997 2.00
2 Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991 1.95
3 Further advances in the management of malignant teratomas of the testis and other sites. Lancet 1983 1.80
4 Accurate quantification of 131I distribution by gamma camera imaging. Eur J Nucl Med 1990 1.78
5 Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984). Br J Obstet Gynaecol 1986 1.53
6 Tumour-marker levels and prognosis in malignant teratoma of the testis. Br J Cancer 1980 1.49
7 Current optimum management of anaplastic germ cell tumours of the testis and other sites. Br J Urol 1986 1.48
8 In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines. Br J Cancer 1999 1.42
9 Chemotherapy of advanced malignant teratomas. Br J Cancer 1980 1.40
10 The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 1989 1.35
11 Characterization of immune complexes in serum by adsorption on staphylococcal protein A: model studies and application to sera of rats bearing a gross virus-induced lymphoma. J Immunol 1978 1.33
12 Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital. Cancer 1983 1.31
13 Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer 1994 1.18
14 Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 1997 1.16
15 What sort of oncology team should treat testicular teratoma? Lancet 1985 1.16
16 Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody. Lancet 1982 1.15
17 Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989 1.14
18 Phage libraries for generation of clinically useful antibodies. Lancet 1994 1.13
19 Recent advances in tumour imaging. Use of radiolabelled antitumour antibodies. Biochim Biophys Acta 1985 1.12
20 Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. Eur J Surg Oncol 2009 1.12
21 The value of carcinoembryonic antigen measurement in clinical practice. Ann Clin Biochem 1984 1.11
22 Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br J Cancer 1990 1.10
23 Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br J Cancer 1993 1.08
24 Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer 1988 1.06
25 Safety of surveillance in the management of stage I anaplastic germ cell tumours of the testis. Br J Urol 1988 1.05
26 Preparation and properties of mouse monoclonal antibody (W14A) to human chorionic gonadotropin. Int J Cancer 1984 1.04
27 Management of resistant gestational trophoblastic tumors. J Reprod Med 1998 1.02
28 Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010 1.02
29 Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol 1991 1.01
30 Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br J Cancer 1989 1.01
31 The effect of radiosensitizers on radio-immunotherapy, using 131I-labelled anti-CEA antibodies in a human colonic xenograft model. Int J Cancer 1991 1.00
32 Comparison of anti-fetal colonic microvillus and anti-CEA antibodies in peroperative radioimmunolocalisation of colorectal cancer. Br J Cancer 1990 1.00
33 Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 2000 1.00
34 Extended glycoprotein structure of the seven domains in human carcinoembryonic antigen by X-ray and neutron solution scattering and an automated curve fitting procedure: implications for cellular adhesion. J Mol Biol 1996 0.99
35 Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 2001 0.99
36 Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 2000 0.98
37 CD44 is associated with proliferation in normal and neoplastic human colorectal epithelial cells. Eur J Cancer 1993 0.98
38 Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy. Cancer Chemother Pharmacol 1982 0.97
39 Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br J Cancer 1996 0.96
40 A mouse model for calculating the absorbed beta-particle dose from (131)I- and (90)Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumor. Radiat Res 2001 0.96
41 Bone disease in testicular and extragonadal germ cell tumours. Br J Cancer 1988 0.95
42 Identification of a human ribosomal protein mRNA with increased expression in colorectal tumours. Biochim Biophys Acta 1989 0.95
43 Radioimmunolocalization of tumours by external scintigraphy after administration of 131I antibody to human chorionic gonadotrophin: preliminary communication. J R Soc Med 1980 0.94
44 The effect of second antibody clearance on the distribution and dosimetry of radiolabelled anti-CEA antibody in a human colonic tumor xenograft model. Int J Cancer 1989 0.94
45 Gestational and nongestational trophoblastic tumors distinguished by DNA analysis. Cancer 1992 0.93
46 Successful management of metastatic and primary germ cell tumors in the brain. Cancer 1986 0.93
47 Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model. Br J Cancer 1994 0.93
48 Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer 2000 0.93
49 Optimum management of pineal germ cell tumours. Clin Oncol (R Coll Radiol) 1991 0.93
50 Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy. Br J Cancer 1994 0.92
51 A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer 1991 0.92
52 Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J 2000 0.92
53 Fertility after chemotherapy for male and female germ cell tumours. Int J Androl 1987 0.92
54 Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996 0.91
55 Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 1999 0.91
56 Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer 2001 0.91
57 Is ectopic production of human chorionic gonadotrophin (hCG) or alpha fetoprotein (AFP) by tumours a marker of chemosensitivity? Eur J Cancer Clin Oncol 1986 0.91
58 Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J Immunol Methods 1995 0.90
59 The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br J Cancer 1994 0.90
60 Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli. Int J Cancer 1994 0.90
61 Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy. Br J Cancer 1992 0.89
62 A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma. Int J Cancer 1995 0.89
63 The value of radioimmunoguided surgery in first and second look laparotomy for colorectal cancer. Dis Colon Rectum 1991 0.89
64 A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res 2001 0.89
65 Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol 1997 0.89
66 Placental site trophoblastic tumor: molecular analysis and clinical experience. Clin Cancer Res 1996 0.88
67 Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer 1996 0.88
68 Doppler assessment of the uterine circulation and the clinical behaviour of gestational trophoblastic tumours requiring chemotherapy. Br J Cancer 1992 0.87
69 Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody. Hum Gene Ther 1998 0.87
70 Fertility after chemotherapy for ovarian germ cell tumours. Br J Obstet Gynaecol 1987 0.87
71 Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits. Br J Cancer 1988 0.86
72 Preliminary Doppler studies on the uterine artery and myometrium in trophoblastic tumours requiring chemotherapy. Br J Obstet Gynaecol 1990 0.85
73 Clearance of injected radioactively labelled antibodies to tumour products by liposome-bound second antibodies. Oncodev Biol Med 1983 0.85
74 Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. Br J Cancer 1996 0.85
75 Doppler time velocity waveform studies of the uterine artery and uterus. Br J Obstet Gynaecol 1989 0.85
76 Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody. Br J Cancer 1995 0.85
77 Pellagra secondary to 5-fluorouracil. Br J Dermatol 1993 0.85
78 A serum factor with potential as a tumour marker in malignant lymphoma. Br J Cancer 1980 0.84
79 The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma. Br J Cancer 1987 0.84
80 Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer Immunol Immunother 2001 0.84
81 The management of high-risk choriocarcinoma. Semin Oncol 1982 0.84
82 Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol 2000 0.84
83 Use of second antibody in radioimmunotherapy. NCI Monogr 1987 0.84
84 Analysis of radioimmunodetection of tumors by the subtraction technique. J Nucl Med 1984 0.84
85 Potential for cure in metastatic ovarian teratomas and dysgerminomas. Br J Obstet Gynaecol 1982 0.83
86 The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy. Br J Cancer 1989 0.83
87 Mathematical model of antibody targeting: important parameters defined using clinical data. Phys Med Biol 2001 0.83
88 Preliminary observations on the microdistribution of labelled antibodies in human colonic adenocarcinoma xenografts: relevance to microdosimetry. Br J Cancer 1990 0.83
89 The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours. Br J Urol 1994 0.83
90 Taking engineered anti-CEA antibodies to the clinic. J Immunol Methods 1999 0.82
91 Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 1995 0.82
92 In situ and slot hybridization analysis of RNA in colorectal tumours and normal colon shows distinct distributions of mitochondrial sequences. J Pathol 1990 0.82
93 Technetium-99m radiolabeling using a phage-derived single-chain Fv with a C-terminal cysteine. J Nucl Med 1996 0.82
94 In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. Immunotechnology 1996 0.82
95 Effective treatment for malignant mediastinal teratoma. Thorax 1983 0.81
96 Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: a comparative study using the linear--quadratic formulation. Int J Radiat Biol 2001 0.81
97 Ultrasonic morphology of the uterus and ovaries after treatment of invasive mole and gestational choriocarcinoma. Br J Radiol 1990 0.81
98 Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model. Int J Cancer 1994 0.80
99 A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy. Cancer Chemother Pharmacol 1990 0.80
100 Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. Br J Cancer 1999 0.80
101 Radioimmunolocalization and selection for surgery in recurrent colorectal cancer. Br J Surg 1986 0.80
102 Clinical applications of phage-derived sFvs and sFv fusion proteins. Dis Markers 2000 0.80
103 A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. Int J Radiat Oncol Biol Phys 1999 0.79
104 Surgery, chemotherapy and whole abdominal radiotherapy in the management of advanced ovarian carcinoma. Clin Radiol 1987 0.79
105 Histamine, leukotriene C4 and interleukin-2 increase antibody uptake into a human carcinoma xenograft model. Br J Cancer 1991 0.79
106 Clinical value of imaging using antibody to alpha fetoprotein in germ cell tumours. Nuklearmedizin 1989 0.79
107 Combined cytotoxic and progestogen therapy for advanced breast cancer. Cancer 1978 0.79
108 Improved radioimmunodetection of tumours using liposome-entrapped antibody. Biochim Biophys Acta 1983 0.79
109 Localization of CEA messenger RNA by in situ hybridization in normal colonic mucosa and colorectal adenocarcinomas. J Pathol 1992 0.78
110 Quantitation in 131I-radioimmunotherapy using SPECT. Int J Cancer Suppl 1988 0.78
111 Cytoreductive surgery in disseminated non-seminomatous germ cell tumours of testis. Br J Surg 1991 0.78
112 Circulating immune complexes as markers of response to chemotherapy in malignant teratomas and gestational trophoblastic tumours. Br J Cancer 1982 0.77
113 Successful treatment of malignant testicular teratoma with brain metastases. Br Med J 1979 0.77
114 Effect of cyclosporine on immunogenicity of a bacterial enzyme carboxypeptidase G2 in ADEPT. Transplant Proc 1996 0.77
115 Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle. Br J Cancer 1998 0.77
116 Single agent etoposide in gestational trophoblastic tumours. Experience at Charing Cross Hospital 1978-1987. Eur J Cancer Clin Oncol 1988 0.76
117 Radioimmunolocalisation of cerebral tumours. Prog Exp Tumor Res 1985 0.76
118 In vivo uptake of 131I-5-iodo-2-deoxyuridine by malignant tumours in man. Br J Cancer 1991 0.76
119 Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images. Cancer Biother Radiopharm 2001 0.76
120 Anaphylactic reaction to radioimmunotherapy despite plasmapheresis to remove anti-mouse antibodies. J R Soc Med 2000 0.75
121 Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancer. Clin Exp Immunol 1984 0.75
122 Identification of PEG-precipitable serum factor associated with malignant lymphoma as C-reactive protein. Br J Cancer 1983 0.75
123 Toxoplasma encephalitis complicating Hodgkin's disease. J Clin Pathol 1975 0.75
124 Hydroxyproline excretion in infantile gastroenteritis. J Clin Pathol 1977 0.75
125 Antibody imaging to locate a placental site trophoblastic tumour following a complete hydatidiform mole. J R Soc Med 1989 0.75
126 Sensible prescribing. III. Acute otitis media and sore throat. Practitioner 1975 0.75
127 Carcinoembryonic antigen levels in germ cell tumours. Int J Biol Markers 1989 0.75
128 The role of abdominal surgery in the treatment of advanced testicular germ cell tumours. Br J Surg 1982 0.75
129 Teratomas of the ovary. Br Med J 1979 0.75
130 Chemotherapy for germ-cell tumours. Lancet 1983 0.75
131 Cytotoxic drugs and sterility. Lancet 1981 0.75
132 The current management of testicular cancer. Br J Urol 1987 0.75
133 Weekly etoposide, methotrexate and actinomycin D, alternating with cyclophosphamide plus vincristine (EMA/CO): a phase II study in advanced gastric carcinoma. Clin Oncol (R Coll Radiol) 1991 0.75
134 Lettsomian Lecture. Selective cancer therapy: is it attainable with engineered antibodies and gene therapy? Trans Med Soc Lond 1999 0.75
135 The importance of measuring quality of life in phase I/II trials of cancer therapy--the effects of antibody targeted therapy: Part I. Eur J Cancer Care (Engl) 1997 0.75
136 Treatment of small cell lung cancer by eight weeks chemotherapy. Med Oncol Tumor Pharmacother 1989 0.75
137 The clinical application of a dual head gamma camera with coincidence detection in 20 women with suspected ovarian cancer. BJOG 2001 0.75
138 Training for coronary care with an arrhythmia simulator. Nurs Times 1972 0.75
139 UICC/CRC conference on targeted cancer therapy. Royal Free Hospital School of Medicine, London, December 17-19, 1991. Int J Cancer 1993 0.75
140 The effect of splenectomy on the haematological response to radiotherapy in Hodgkin's disease. Br J Haematol 1974 0.75
141 Quantitative distribution of 131I-labelled monoclonal antibodies administered by the intra-ventricular route. Eur J Cancer 1990 0.75
142 Liposomally entrapped second antibody. Lancet 1983 0.75
143 [Treatment of advanced testicular teratoma]. Actas Urol Esp 1980 0.75
144 EMOP/CA chemotherapy for the treatment of aggressive non-Hodgkin's lymphomas. Eur J Cancer Clin Oncol 1989 0.75
145 Histamine but neither angiotensin nor vasopressin increases antibody uptake into xenograft colorectal liver metastases. Br J Surg 1993 0.75
146 Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody. Eur J Cancer 1998 0.75
147 Treatment of patients with poor prognosis anaplastic germ cell tumours (AGCT) of the testis and other sites. Int J Androl 1987 0.75
148 The management of high-risk gestational trophoblastic tumours (GTT). Int J Gynaecol Obstet 1998 0.75
149 A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. Phys Med Biol 1999 0.75
150 Fertility after chemotherapy for ovarian germ cell tumors. J Clin Oncol 1988 0.75
151 The value of carcinoembryonic antigen in clinical practice. Br J Hosp Med 1987 0.75
152 Lumbar pain in stage 1 testicular germ cell tumours: a symptom preceding radiological abnormality. Br J Urol 1989 0.75
153 Liposomes as aids to tumour detection. Biochem Soc Trans 1984 0.75
154 Augmentation of vincristine-induced thrombocytosis by norethisterone. Eur J Cancer 1979 0.75
155 Sensible prescribing. V.-Diarrhoea and vomiting. Practitioner 1975 0.75
156 Sensible prescribing. Practitioner 1975 0.75
157 IV.--Pneumonia. Practitioner 1975 0.75